CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A
Protein & Cell · 01.10.2024 · 15 (10) · 744-765
DOI: 10.1093/procel/pwae010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein & Cell, online erschienen am 13.03.2024. Verfasst von Dandan Feng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Cancer and Microbiome, State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Ca…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Hypoxia-Inducible Factor 1, alpha Subunit, Protein-Arginine N-Methyltransferases, Cell Proliferation. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Coactivator-associated arginine methyltransferase 1 (CARM1) promotes the development and metastasis of estrogen receptor alpha (ERα)-positive breast cancer. The function of CARM1 in triple-negative breast cancer (TNBC) is still unclear and requires further exploration. Here, we report that CARM1 promotes proliferation, epithelial–mesenchymal transition, and stemness in TNBC. CARM1 is upregulated in multiple cancers and its expression correlates with breast cancer progression. Genome-wide analysis of CARM1 showed that CARM1 is recruited by hypoxia-inducible factor-1 subunit alpha (HIF1A) and occupy the promoters of CDK4, Cyclin D1, β-Catenin, HIF1A, MALAT1, and SIX1 critically involved in cell cycle, HIF-1 signaling pathway, Wnt signaling pathway, VEGF signaling pathway, thereby modulating the proliferation and invasion of TNBC cells. We demonstrated that CARM1 is physically associated with and directly interacts with HIF1A. Moreover, we found that ellagic acid, an inhibitor of CARM1, can suppress the proliferation and invasion of TNBC by directly inhibiting CDK4 expression. Our research has determined the molecular basis of CARM1 carcinogenesis in TNBC and its effective natural inhibitor, which may provide new ideas and drugs for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Cancer and Microbiome, State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking…
- Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
- Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan 250033, China.
- Department of Cancer Center, The Second Hospital of Shandong University, Jinan 250033, China.
- Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China.
ORCID-Profile: Jie Gao, Ruiqiong Liu, Hefen Yu, Wei Huang, Yan Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Feng, D., Gao, J., Liu, R., Liu, W., Gao, T., Yang, Y., Zhang, D., Yang, T., Yin, X., Yu, H., Huang, W., & Wang, Y. (2024). CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A. Protein & Cell, 15(10), 744-765. https://doi.org/10.1093/procel/pwae010
Vancouver
Feng D, Gao J, Liu R, Liu W, Gao T, Yang Y, et al. CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A. Protein & Cell. 2024;15(10):744-765. doi:10.1093/procel/pwae010
BibTeX
@article{Feng2024,
author = {Feng, Dandan and Gao, Jie and Liu, Ruiqiong and Liu, Wei and Gao, Tianyang and Yang, Yunkai and Zhang, Die and Yang, Tianshu and Yin, Xin and Yu, Hefen and Huang, Wei and Wang, Yan},
title = {CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A},
journal = {Protein & Cell},
year = {2024},
volume = {15},
number = {10},
pages = {744--765},
doi = {10.1093/procel/pwae010}
}
EUVIMED